Alfredo Sadun
Ophthalmology · Pasadena, CANPI 1841342367
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Chiesi USA, Inc. accounts for 99.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $13,120 and has fallen 62.8% since, to $4,877 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 14 payments — averaging $2321.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$32K
- Amgen$75
- Catalyst Pharmaceuticals, Inc.$62
- Novartis$24
- UCB, Inc.$15
Across 7 payments — averaging $1791.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- PTC Therapeutics, Inc.$13K
What the payments were for
- Consulting fees$19,20059%
- Speaking & faculty fees$5,50017%
- Travel & lodging$7,62023%
- Food & beverage$1610%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 10 | $32,320 |
| Amgen | 1 | $75 |
| Catalyst Pharmaceuticals, Inc. | 1 | $62 |
| Novartis | 1 | $24 |
| UCB, Inc. | 1 | $15 |
How this compares
$32,496 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 30 | $29,751 |
| Cyclosporine | 13 | $3,651 |
| Pentoxifylline | 56 | $3,467 |
| Pyridostigmine Bromide | 20 | $1,678 |
| Latanoprost | 25 | $242 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Pasadena
- Srinivas SaddaPasadena$1M
- Michael IpPasadena$181K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.